RNA-based gene therapy in autoimmune disease

The Problem

- Immunosuppressive drugs are the standard-of-care for most autoimmune diseases.
- · Current treatments cause significant adverse effects and morbidity.
- More selective treatments needed for refractory diseases.

The Solution

Our team is developing a new autoimmune therapy by targeting negative regulators of inflammatory cytokine signaling using mRNA-LNP delivery. This will enhance intracellular expression of target proteins to switch off damaging inflammatory signalling from subgroups of cytokines.

Our Program

Progress:

• Currently developing a PoC mRNA-LNP delivery system to increase target expression and assess its ability to switch off inflammatory cytokine signalling.

Seeking partnerships with expertise in mRNA-LNP delivery



*= Target can be disclosed under a CDA

Our Team

Prof. Sandra Nicholson, Cytokine signalling

A/Prof. James Vince, Inflammation, mRNA-LNP

Onisha Patel, PhD, Business Development, patel.o@wehi.edu.au

